JP2010534200A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010534200A5 JP2010534200A5 JP2010516587A JP2010516587A JP2010534200A5 JP 2010534200 A5 JP2010534200 A5 JP 2010534200A5 JP 2010516587 A JP2010516587 A JP 2010516587A JP 2010516587 A JP2010516587 A JP 2010516587A JP 2010534200 A5 JP2010534200 A5 JP 2010534200A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- clec9a
- binding agent
- composition
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims 18
- 102000036639 antigens Human genes 0.000 claims 18
- 108091007433 antigens Proteins 0.000 claims 18
- 239000011230 binding agent Substances 0.000 claims 18
- 238000000034 method Methods 0.000 claims 18
- 239000000203 mixture Substances 0.000 claims 13
- 210000004027 cell Anatomy 0.000 claims 12
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 8
- 230000028993 immune response Effects 0.000 claims 8
- 230000004044 response Effects 0.000 claims 8
- 230000001404 mediated effect Effects 0.000 claims 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims 5
- 108020004414 DNA Proteins 0.000 claims 4
- 108010032595 Antibody Binding Sites Proteins 0.000 claims 3
- 206010020751 Hypersensitivity Diseases 0.000 claims 3
- 210000001744 T-lymphocyte Anatomy 0.000 claims 3
- 239000002671 adjuvant Substances 0.000 claims 3
- 239000000556 agonist Substances 0.000 claims 3
- 239000005557 antagonist Substances 0.000 claims 3
- 206010003246 arthritis Diseases 0.000 claims 3
- 210000004443 dendritic cell Anatomy 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 238000000338 in vitro Methods 0.000 claims 3
- 230000004936 stimulating effect Effects 0.000 claims 3
- 238000002054 transplantation Methods 0.000 claims 3
- 108020005544 Antisense RNA Proteins 0.000 claims 2
- 229940123189 CD40 agonist Drugs 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 108090000994 Catalytic RNA Proteins 0.000 claims 2
- 102000053642 Catalytic RNA Human genes 0.000 claims 2
- 102000053602 DNA Human genes 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 2
- 108010002352 Interleukin-1 Proteins 0.000 claims 2
- 102000043129 MHC class I family Human genes 0.000 claims 2
- 108091054437 MHC class I family Proteins 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000012902 Nervous system disease Diseases 0.000 claims 2
- 208000025966 Neurological disease Diseases 0.000 claims 2
- 108020004459 Small interfering RNA Proteins 0.000 claims 2
- 102100040247 Tumor necrosis factor Human genes 0.000 claims 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims 2
- 230000001363 autoimmune Effects 0.000 claims 2
- 239000003184 complementary RNA Substances 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 238000000968 medical method and process Methods 0.000 claims 2
- 108020004999 messenger RNA Proteins 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 208000023504 respiratory system disease Diseases 0.000 claims 2
- 229930002330 retinoic acid Natural products 0.000 claims 2
- 108091092562 ribozyme Proteins 0.000 claims 2
- 229960001727 tretinoin Drugs 0.000 claims 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000031229 Cardiomyopathies Diseases 0.000 claims 1
- 208000015943 Coeliac disease Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010014561 Emphysema Diseases 0.000 claims 1
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010057190 Respiratory tract infections Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 206010040070 Septic Shock Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 108010067390 Viral Proteins Proteins 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 208000026816 acute arthritis Diseases 0.000 claims 1
- 230000000172 allergic effect Effects 0.000 claims 1
- 230000014102 antigen processing and presentation of exogenous peptide antigen via MHC class I Effects 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 238000010322 bone marrow transplantation Methods 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 230000003412 degenerative effect Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 206010014665 endocarditis Diseases 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 230000002134 immunopathologic effect Effects 0.000 claims 1
- 239000012678 infectious agent Substances 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 210000000274 microglia Anatomy 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 231100000252 nontoxic Toxicity 0.000 claims 1
- 230000003000 nontoxic effect Effects 0.000 claims 1
- 244000045947 parasite Species 0.000 claims 1
- 244000052769 pathogen Species 0.000 claims 1
- 230000001717 pathogenic effect Effects 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- 208000020029 respiratory tract infectious disease Diseases 0.000 claims 1
- 201000003068 rheumatic fever Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 206010039083 rhinitis Diseases 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 230000009870 specific binding Effects 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 206010043778 thyroiditis Diseases 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 231100000331 toxic Toxicity 0.000 claims 1
- 230000002588 toxic effect Effects 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US92999907P | 2007-07-20 | 2007-07-20 | |
| US60/929,999 | 2007-07-20 | ||
| GB0805159.1 | 2008-03-19 | ||
| GBGB0805159.1A GB0805159D0 (en) | 2008-03-19 | 2008-03-19 | Immune modulation via C-type lectin |
| PCT/GB2008/002504 WO2009013484A1 (en) | 2007-07-20 | 2008-07-21 | Immune modulation via c-type lectin |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010534200A JP2010534200A (ja) | 2010-11-04 |
| JP2010534200A5 true JP2010534200A5 (enExample) | 2011-09-08 |
| JP5577246B2 JP5577246B2 (ja) | 2014-08-20 |
Family
ID=39356783
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010516587A Expired - Fee Related JP5577246B2 (ja) | 2007-07-20 | 2008-07-21 | Ｃ型レクチンを介する免疫 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US8580266B2 (enExample) |
| EP (1) | EP2185586B1 (enExample) |
| JP (1) | JP5577246B2 (enExample) |
| CN (1) | CN101896500B (enExample) |
| AU (1) | AU2008278831B2 (enExample) |
| CA (1) | CA2693277A1 (enExample) |
| DK (1) | DK2185586T3 (enExample) |
| ES (1) | ES2557935T3 (enExample) |
| GB (1) | GB0805159D0 (enExample) |
| HR (1) | HRP20160033T1 (enExample) |
| HU (1) | HUE026387T2 (enExample) |
| SI (1) | SI2185586T1 (enExample) |
| WO (1) | WO2009013484A1 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0815848A2 (pt) | 2007-08-30 | 2017-06-06 | The Burnet Inst | composto, linhagem de célula que produz anticorpo estável, composição, métodos para modular uma resposta imune em um indivíduo e para tratar e/ou prevenir uma doença, usos de um composto e/ou uma composição e de células dendríticas ou precursores das mesmas, métodos para enriquecer e detectar células dendríticas ou um subconjunto ou precursores das mesmas, polipeptídeo, polinucleotídeo vetor, célula hospedeira, planta transgênica, animal não humano transgênico, extrato, processo para preparar um composto ou um polipeptídeo, população enriquecida de células dendríticas e/ou precursores das mesmas, população de célula dendrítica expandida e/ou precursores das mesmas, métodos para identificar uma molécula que se liga a um polipeptídeo e para triar quanto a um composto que se liga a um polipeptídeo, uso de um polipeptídeo, um polinucleotídeo, um vetor, uma célula hospedeira, uma planta transgênica, um extrato, uma população de célula e/ou uma composição, método para produzir um composto, e, kit. |
| US20110110861A1 (en) * | 2008-05-13 | 2011-05-12 | Mireille Hanna Lahoud | Methods of Detecting Cells with a Disrupted Cell Membrane, Cells Infected with A Pathogen, Dying Cells or Dead Cells |
| CA2755983A1 (en) * | 2009-03-23 | 2010-09-30 | The Walter And Eliza Hall Institute Of Medical Research | Compounds and methods for modulating an immune response |
| GB201006768D0 (en) | 2010-04-22 | 2010-06-09 | Cancer Rec Tech Ltd | Method for obtaining dendritic cells |
| KR20130036246A (ko) * | 2010-05-07 | 2013-04-11 | 베일러 리서치 인스티튜트 | 사람 ｃｄ8+ ｔ 세포의 수지상 세포 면역수용체(ｄｃｉｒ)-매개 교차프라이밍 |
| WO2013088136A1 (en) | 2011-12-12 | 2013-06-20 | Ahrens Susan | Ligand for dngr-1 receptor |
| EP2901156B1 (en) | 2012-09-26 | 2018-06-20 | Cook Biotech Incorporated | Medical device design, manufacture and testing systems |
| US20160015803A1 (en) * | 2014-07-18 | 2016-01-21 | Ross Kedl | Immunostimulatory combinations and use thereof |
| AU2015294059B2 (en) * | 2014-07-21 | 2019-03-14 | Société des Produits Nestlé S.A. | Nutritional products to promote safe swallowing for individuals with dysphagia |
| CN104789689B (zh) * | 2015-05-13 | 2018-10-02 | 北京泱深生物信息技术有限公司 | 作为肺腺癌诊治靶标的clec9a基因 |
| AU2016304597B2 (en) * | 2015-08-06 | 2022-10-06 | Memorial Sloan Kettering Cancer Center | Methods and compositions for tumor therapy |
| CN115850521A (zh) * | 2016-02-05 | 2023-03-28 | 奥里尼斯生物科学私人有限公司 | 靶向性治疗剂及其用途 |
| US11661455B2 (en) | 2016-02-05 | 2023-05-30 | Orionis Biosciences BV | Chimeric protein comprising an interferon alpha 2mutant and a PD-L1 binding moiety |
| CN105924501B (zh) * | 2016-04-28 | 2019-04-02 | 郑州大学 | 靶向Clec9a的亲和肽WH肽 |
| US11630103B2 (en) | 2016-08-17 | 2023-04-18 | The Broad Institute, Inc. | Product and methods useful for modulating and evaluating immune responses |
| CA3069930A1 (en) | 2017-08-09 | 2019-02-14 | Orionis Biosciences Inc. | Cd8 binding agents |
| CN111328286B (zh) | 2017-08-09 | 2024-08-23 | 奥里尼斯生物科学有限公司 | Pd-1和pd-l1结合剂 |
| AU2018313810B2 (en) * | 2017-08-09 | 2025-05-15 | Orionis Biosciences BV | Clec9A binding agents and use thereof |
| JPWO2019244973A1 (ja) * | 2018-06-20 | 2021-07-08 | 中外製薬株式会社 | 標的細胞に対する免疫反応を活性化する方法およびその組成物 |
| MA53438A (fr) | 2018-08-24 | 2021-09-15 | Codiak Biosciences Inc | Vésicules extracellulaires ciblant des cellules dendritiques et utilisations associées |
| CA3118892A1 (en) | 2018-11-08 | 2020-05-14 | Orionis Biosciences, Inc. | Modulation of dendritic cell lineages |
| EP3908263A4 (en) * | 2019-01-08 | 2023-04-19 | University of Georgia Research Foundation, Inc. | TARGETED NANOPARTICLES AND THEIR USES IN FUNGAL INFECTIONS |
| JP7546924B2 (ja) * | 2019-03-01 | 2024-09-09 | 国立大学法人 筑波大学 | アレルギー疾患を処置することに用いるための組成物 |
| US12351614B2 (en) | 2019-03-28 | 2025-07-08 | Orionis Biosciences, Inc. | CLEC9A-based chimeric protein complexes |
| CN111544592B (zh) * | 2020-03-13 | 2022-05-03 | 中山大学附属第一医院 | 模式识别受体Dectin-1抑制剂对受体移植物的免疫保护及诱导免疫耐受的应用 |
| EP3892739A1 (en) * | 2020-04-09 | 2021-10-13 | Centre Léon Bérard | Type iii interferon for use as a biomarker to predict response to a cancer treatment |
| GB202011859D0 (en) | 2020-07-30 | 2020-09-16 | Francis Crick Institute Ltd | Cytosolic delivery |
| CA3248697A1 (en) | 2022-04-21 | 2023-10-26 | The Francis Crick Institute Limited | BISPECIFIC LIAISON OFFICERS |
| WO2024018062A1 (en) | 2022-07-21 | 2024-01-25 | The Francis Crick Institute Limited | Immunoconjugate |
| GB202401381D0 (en) | 2024-02-02 | 2024-03-20 | Francis Crick Institute Ltd | Anti-actin antibodies |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020042386A1 (en) * | 2000-01-31 | 2002-04-11 | Rosen Craig A. | Nucleic acids, proteins, and antibodies |
| WO2001055309A2 (en) * | 2000-01-31 | 2001-08-02 | Human Genome Sciences, Inc. | Nucleic acids, proteins, and antibodies |
| DE10142994A1 (de) * | 2001-09-01 | 2003-03-27 | Keiper Gmbh & Co | Längseinsteller für einen Fahrzeugsitz |
| CA2469941A1 (en) * | 2001-12-10 | 2003-07-03 | Nuvelo, Inc. | Novel nucleic acids and polypeptides |
-
2008
- 2008-03-19 GB GBGB0805159.1A patent/GB0805159D0/en not_active Ceased
- 2008-07-21 JP JP2010516587A patent/JP5577246B2/ja not_active Expired - Fee Related
- 2008-07-21 EP EP08776024.5A patent/EP2185586B1/en active Active
- 2008-07-21 AU AU2008278831A patent/AU2008278831B2/en not_active Ceased
- 2008-07-21 HR HRP20160033TT patent/HRP20160033T1/hr unknown
- 2008-07-21 WO PCT/GB2008/002504 patent/WO2009013484A1/en not_active Ceased
- 2008-07-21 CN CN200880107621.2A patent/CN101896500B/zh not_active Expired - Fee Related
- 2008-07-21 ES ES08776024.5T patent/ES2557935T3/es active Active
- 2008-07-21 CA CA2693277A patent/CA2693277A1/en not_active Abandoned
- 2008-07-21 US US12/669,940 patent/US8580266B2/en not_active Expired - Fee Related
- 2008-07-21 HU HUE08776024A patent/HUE026387T2/en unknown
- 2008-07-21 SI SI200831558T patent/SI2185586T1/sl unknown
- 2008-07-21 DK DK08776024.5T patent/DK2185586T3/en active
-
2013
- 2013-10-09 US US14/049,563 patent/US9205153B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010534200A5 (enExample) | ||
| Liu et al. | Bacteria-derived nanovesicles enhance tumour vaccination by trained immunity | |
| US11992527B2 (en) | Extracellular vesicles for vaccine delivery | |
| Liu et al. | The immunomodulatory effects of mesenchymal stem cells on regulatory B cells | |
| CN105307725B (zh) | 治疗自身免疫疾病的方法和组合物 | |
| JP2025061056A (ja) | 異なる核酸アジュバントの組み合わせによる、新規Ｔｈ１誘導性アジュバントおよびその用途 | |
| HRP20160033T1 (hr) | Imunološka modulacija preko lectina tipa c | |
| Jung et al. | Enhanced efficacy of therapeutic cancer vaccines produced by co-treatment with Mycobacterium tuberculosis heparin-binding hemagglutinin, a novel TLR4 agonist | |
| Sun et al. | A single ssDNA aptamer binding to mannose-capped lipoarabinomannan of Bacillus Calmette–Guérin enhances immunoprotective effect against tuberculosis | |
| CA2984485A1 (en) | Nanoparticle compositions for sustained therapy | |
| CN111373260A (zh) | 产生调节性免疫细胞的方法及其用途 | |
| EP3600342B1 (en) | Method for designing rig-i ligands | |
| JP2008524237A (ja) | 免疫寛容の誘導又は促進のための方法及び組成物 | |
| WO2007139190A1 (ja) | 免疫刺激オリゴヌクレオチド及びその医薬用途 | |
| JP6004594B2 (ja) | 可溶性メディエーター | |
| AU2021236763A1 (en) | Extracellular vesicles for therapy | |
| JP2023515355A (ja) | 高速ワクチンプラットフォーム | |
| JP2014504158A (ja) | 非コード免疫調節性ｄｎａ構築物 | |
| Romano et al. | A structural view at vaccine development against M. tuberculosis | |
| EP2861719A1 (en) | Compositions and methods for diminishing an immune response | |
| Horng et al. | HBV X protein-based therapeutic vaccine accelerates viral antigen clearance by mobilizing monocyte infiltration into the liver in HBV carrier mice | |
| WO2020081730A2 (en) | Methods and compositions for modulating microenvironment | |
| CN112662695A (zh) | 一种细菌生物膜囊泡（bbv）作为疫苗载体的构建方法和应用 | |
| Sun et al. | Alcaligene s lipid a functions as a superior mucosal adjuvant to monophosphoryl lipid a via the recruitment and activation of CD11b+ dendritic cells in nasal tissue | |
| US20070128670A1 (en) | Methods for the identification and preparation of regulator/suppressor t lymphocytes, compositions and use thereof |